➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Express Scripts
AstraZeneca
Boehringer Ingelheim
Harvard Business School

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,245,819

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,245,819 protect, and when does it expire?

Patent 6,245,819 protects OSPHENA and is included in one NDA.

This patent has forty-one patent family members in twenty-eight countries.

Summary for Patent: 6,245,819
Title: Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
Abstract:This invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.
Inventor(s): Halonen; Kaija (Rusko, FI), Kangas; Lauri (Raisio, FI), DeGregorio; Michael W. (Granite Bay, CA)
Assignee: Hormos Medical Oy, Ltd. (FI) Tess Diagnostics and Pharmaceuticals, Inc. (Granite Bay, CA)
Application Number:09/625,199
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery;

Drugs Protected by US Patent 6,245,819

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes   Start Trial   Start Trial TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE   Start Trial
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes   Start Trial   Start Trial TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,245,819

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 300289   Start Trial
Australia 2001258449   Start Trial
Australia 5844901   Start Trial
Bulgaria 107472   Start Trial
Bulgaria 65943   Start Trial
Brazil 0112659   Start Trial
Canada 2416480   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
McKinsey
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.